

### **In the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method of Use of using a mutant form of EtxB or CtxB ~~to deliver comprising~~ delivering an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.
2. (Currently amended) The method of Use according to claim 1 wherein the agent is selected from the group consisting of a peptide or protein of interest (POI); ~~an antigen; an antigenic determinant; an antibody; and a nucleotide sequence of interest (NOI).~~
3. (Currently amended) The method Use according to claim 2 wherein the agent ~~may be~~ is linked to a membrane translocating or fusigenic peptide.
4. (Currently amended) The method Use according to claim 3 wherein the membrane translocating or fusigenic peptide ~~may comprises~~ elements of the Pol-loop segment corresponding to a domain in the C-terminal region of HSV-1 polymerase.
5. (Currently amended) The method Use according to claim 2, ~~3 or 4~~ wherein the antigen is selected from the group consisting of a viral antigen, a bacte-

rial antigen, a parasitic antigen; and a ~~tumour~~tumor associated antigen (TAA).

6. (Currently amended) The method ~~Use according to any one of claims 1-5~~  
claim 1 wherein the agent is delivered into a vesicular compartment of the target cell.
7. (Currently amended) The method ~~Use according to any one of claims 1-6~~  
claim 1 wherein the target cell comprises at least one constituent selected from the group consisting of cytosol, nucleus, and organelle, and wherein the agent is targeted to the cytosol and/or the nucleus and/or an organelle of the target cell.
8. (Currently amended) The method of claim 1 ~~Use according to any one of the preceding claims~~ wherein the target cell is an antigen presenting cell (APC).
9. (Currently amended) The method of claim 1 ~~Use according to any one of the preceding claims~~ wherein the mutant comprises a mutation in the region spanning amino acid residues E51-I58 of the  $\beta$ 4- $\alpha$ 2 loop of CtxB or EtxB.
10. (Currently amended) The method of claim 9 ~~Use according to claim 9~~ wherein the mutant comprises a mutation at amino acid residues 51, 56 and/or 57 of the  $\beta$ 4- $\alpha$ 2 loop.
11. (Currently amended) The method ~~Use according to of~~ claim 9 or claim 10 wherein the mutant comprises a H57A or H57S mutation.

12. (Currently amended) A method of Use of preparing a medicament comprising providing a mutant of EtxB or CtxB according to any one of the preceding claims in the preparation of a medicament to, wherein the mutant is capable of delivering an exogenous peptide into the MHC Class I antigen processing and presentation pathways to elicit a CTL response.
13. (Currently amended) Use The method according to claim 12 wherein the exogenous peptide is any one of the agents as defined in claim 5. an agent selected from the group consisting of a peptide or protein of interest (POI), an antigen, an antigenic determinant, an antibody, and a nucleotide sequence of interest (NOI).
14. (Currently amended) A method of using The use of a mutant of EtxB or CtxB for separate, simultaneous or combined use to treat a disease or a condition in a subject in need of same comprising as defined in any one of claims 1-13 in the preparation of administering a medicament comprising a mutant of EtxB or CtxB wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB. for separate, simultaneous or combined use to treat a disease or a condition in a subject in need of same.
15. (Currently amended) A method of treating a disease or condition in a subject in need of same wherein the method comprises:
  - (i) \_\_\_\_\_ providing a target cell; and
  - (ii) delivering an agent to the target cell using a mutant of EtxB or CtxB wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB. as defined in any one of claims 1-13.

16. (Currently amended) A method according to claim 15 ~~or the use according to any one of claims 12-14~~ wherein the disease or condition is a viral infection or a cancer.
17. (Currently amended) A method of delivering an agent using a mutant to a target cell wherein the method comprises:
  - (i) providing a target cell;
  - (ii) contacting the cell with a mutant of EtxB or CtxB wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB~~the mutant as defined in any one of claims 1-13;~~ and
  - (iii) monitoring for the presence of the agent in the target cell.
18. (Original) A method according to claim 17 wherein the agent is delivered to a vesicular compartment, and/or cytosol and/or nucleus and/or an organelle of the target cell.
19. (Currently amended) A composition, preferably a pharmaceutical composition, comprising a mutant of EtxB or CtxB wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB as defined in any one of claims 1-13 and at least one pharmaceutically acceptable constituent selected from the group consisting of -carrier(s), diluent(s), excipient(s) or adjuvant or any and combinations thereof.
20. (Currently amended) A composition comprising a mutant as defined in any one of ~~claims 1-13~~claim 19 which is a vaccine.

21. (Currently amended) A kit for delivering an agent to a target cell wherein the kit comprises:
- (i) a mutant of EtxB or CtxB wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB~~as defined in any one of claims 1-13;~~
  - (ii) an agent for delivery to the target cell; and optionally
  - (iii) means for detecting the location of the agent in the target cell.
22. (cancelled) ~~The use and the method substantially as defined herein and with reference to the accompanying Figures.~~
23. (New) The method according to claim 12 wherein the agent is linked to a membrane translocating or fusigenic peptide.
24. (New) The method according to claim 23 wherein the membrane translocating or fusigenic peptide comprises elements of the Pol-loop segment corresponding to a domain in the C-terminal region of HSV-1 polymerase.
25. (New) The method according to claim 13, wherein the antigen is selected from the group consisting of a viral antigen, a bacterial antigen, a parasitic antigen; and a tumor associated antigen (TAA).